← Back to Clinical Trials
Recruiting NCT04613193

NCT04613193 Blood Pressure Reduction in Patients With Asymptomatic Aortic VALVE Stenosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04613193
Status Recruiting
Phase
Sponsor Henrik Wiggers
Condition Aortic Valve Stenosis
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2019-03-01
Primary Completion 2031-01-01

Trial Parameters

Condition Aortic Valve Stenosis
Sponsor Henrik Wiggers
Study Type INTERVENTIONAL
Phase N/A
Enrollment 200
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2019-03-01
Completion 2031-01-01
Interventions
Blood presssure reduction

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The aim of this study is to investigate the effect of strict blood pressure control versus conventional care in patients with asymptomatic moderate to severe aortic valve stenosis. The study is a randomized (1:1), open label, controlled intervention trial. Hypothesis: 1. Strict BP control for 12 months reduces the progression of LV remodelling compared to conventional treatment. 2. Strict BP control for 2 years reduces the increase in aortic valve calcification and LV remodelling compared to conventional treatment. 3. Strict BP reduction for up to 10 years reduces the need for aortic valve replacement and cardiovascular events compared to conventional care.

Eligibility Criteria

Inclusion Criteria: * Aortic valve peak velocity (Vmax) of 3.0-5.0 m/s and/or aortic valve area (AVA) ≤ 1.2 cm2 * Blood pressure: SBP \>= 127 mmHg measured by BP-TRU * LVEF ≥ 50% * Age \> 18 years * Safe birth control management (intrauterine devices or hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release)) for women of childbearing potential. * Negative urine-HCG for women of childbearing potential * Ability to understand the written patient information and to give informed consent. Exclusion Criteria: * Symptoms due to AS * Symptomatic orthostatic hypotension and/or one minute standing SBP \< 110 mmHg (16). * Suspicion of secondary hypertension * Participation in other randomized drug study (device studies accepted) * Moderat to severe aortic valve regurgitation e.g. vena contracta \> 5 mm, assessed by echocardiography) * Known or suspected ischemic heart disease (coronary angiography with \>70% ste

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology